Disease relevance of SLC45A3

• These results validate prostein as a prostate-specific marker with potential utility in the diagnosis and treatment of prostate cancer [1].

High impact information on SLC45A3

• The prostein gene is located on chromosome 1 at the WI-9641 locus between q32 and q42 [1].
• Prostein expression is androgen responsive because treatment of LNCaP cells with androgen up-regulates prostein message and protein expression levels [1].
• Immunohistochemical staining using a mouse monoclonal antibody generated against prostein demonstrates that this protein is specifically detected in prostate tissues both at the plasma membrane and in the cytoplasm [1].
• Furthermore, prostein mRNA expression does not appear to be prostate tumor grade related and is restricted exclusively to prostate cell lines [1].
• Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate [2].

Biological context of SLC45A3

• To identify immunogenic CD8+ T-cell epitopes, human leucocyte antigen-A(*)0201-binding peptides were selected from the amino-acid sequence of prostein and were used for the in vitro stimulation of CD8+ T lymphocytes [3].

Anatomical context of SLC45A3

• Prostein-specific CD8 T cell clones specifically recognized prostein-expressing targets, including prostate tumor cell lines expressing the relevant HLA alleles [2].

Analytical, diagnostic and therapeutic context of SLC45A3

• Prostein mRNA is shown to be uniquely expressed in normal and cancerous prostate tissues using Northern blot, eDNA microarray, and real-time PCR analyses [1].
• Our data suggest that prostein is a suitable candidate to be included in a T-cell-based immunotherapy of prostate cancer [3].
• Furthermore, the naturally processed peptide epitopes identified provide tools for the development of peptide-based vaccination strategies against prostate cancer and for monitoring of prostein-specific responses in vaccinated patients [2].

References